S100A9 and myocardial infarction: Furthermore, we have contextualized the therapeutic potential of these hub genes by identifying specific drug-gene interactions, offering a more refined understanding of how agents targeting S100A9 and MMP9 might exert their effects within the specific immune microenvironment of MI.